nach oben

The European Journal of Health Economics

Erschienen in:

01.12.2013 | Original Paper

Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany

verfasst von: Bernhard Ultsch, Ingrid Köster, Thomas Reinhold, Anette Siedler, Gérard Krause, Andrea Icks, Ingrid Schubert, Ole Wichmann

Erschienen in: The European Journal of Health Economics | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

After acquiring a varicella virus infection, the virus can reactivate and cause herpes zoster (HZ)—a painful skin rash. A complication of HZ is long-term persistence of pain after the rash has resolved (so-called postherpetic neuralgia, PHN). We aimed to describe the epidemiology of HZ/PHN and to estimate HZ/PHN-related costs in the German statutory health insurance (SHI) system (~85 % of the total population). Treatment data of one large SHI was utilized, containing data on approximately 240,000 insured and their utilisation of services in 2004–2009. Identification of HZ- and PHN-cases was performed based on ‘International Statistical Classification of Diseases’ and specific medications using a control-group design. Incidences per 1,000 person-years (PY) and cost-of-illness for 1 year following HZ-onset considering the payer and societal perspective were calculated. All amounts were inflated to 2010 Euros. Population-figures were standardised and extrapolated to the total SHI-population in Germany in 2010. A mean annual incidence of 5.79 HZ-cases per 1,000 PY was observed, translating into an estimated 403,625 HZ-cases per year in the total SHI-population. Approximately 5 % of HZ-cases developed PHN. One HZ-case caused on average €210 and €376 of costs from the payer and societal perspective, respectively. The development of PHN generated additional costs of €1,123 (€1,645 societal perspective). Total annual HZ/PHN-related costs were estimated at €182 million (€105 million) to society (payer). HZ and PHN place a considerable burden on the German SHI-system. Since HZ-vaccines will soon be available, a health-economic evaluation of these vaccines should be conducted.

Wutzler, P., Färber, I., Wagenpfeil, S., Bisanz, H., Tischer, A.: Seroprevalence of varicella-zoster virus in the German population. Vaccine 20(1–2), 121–124 (2001)PubMedCrossRef

Breuer, J., Whitley, R.: Varicella zoster virus: natural history and current therapies of varicella and herpes zoster. Herpes 14(Suppl 2), 25–29 (2007)PubMed

Hope-Simpson, R.E.: The nature of herpes zoster: a long-term study and a new hypothesis. Proc. R. Soc. Med. 58, 9–20 (1965)PubMed

Wittek, M., Doerr, H.W., Allwinn, R.: Varicella and herpes zoster. Part 1: virology, epidemiology, clinical picture, laboratory diagnostics. Med Klin (Munich) 105(5), 334–338 (2010). doi:10.1007/s00063-010-1061-3 CrossRef

Schmader, K., Gnann Jr, J.W., Watson, C.P.: The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J. Infect. Dis. 197(Suppl 2), S207–S215 (2008). doi:10.1086/522152 PubMedCrossRef

Drolet, M., Brisson, M., Levin, M.J., Schmader, K.E., Oxman, M.N., Johnson, R.W., et al.: A prospective study of the herpes zoster severity of illness. Clin. J. Pain 26(8), 656–666 (2010). doi:10.1097/AJP.0b013e3181eef686 PubMed

Opstelten, W., Eekhof, J., Neven, A.K., Verheij, T.: Treatment of herpes zoster. Can. Fam. Physician 54(3), 373–377 (2008)PubMed

Forbes, H., Thomas, S., Langan, S.: The epidemiology and prevention of herpes zoster. Curr. Dermatol. Rep. 1(1), 39–47 (2012). doi:10.1007/s13671-011-0004-4 CrossRef

Edmunds, W.J., Brisson, M., Rose, J.D.: The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 19(23–24), 3076–3090 (2001). doi: 10.1016/S0264-410X(01)00044-5 PubMedCrossRef

10.

Hope-Simpson, R.E.: Postherpetic neuralgia. J. R. Coll. Gen. Pract. 25(157), 571–575 (1975)PubMed

11.

Jericho, B.G.: Postherpetic neuralgia: a review. Internet J. Pain Symptom Control Palliat. Care 8(1) (2010). doi: 10.5580/124b

12.

EMA: European Public Assessment Report (EPAR) for ZOSTAVAX summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000674/WC500053462.pdf (2006). Accessed 18 March 2011

13.

Oxman, M.N., Levin, M.J., Johnson, G.R., Schmader, K.E., Straus, S.E., Gelb, L.D., et al.: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352(22), 2271–2284 (2005). doi:10.1056/NEJMoa051016 PubMedCrossRef

14.

Tseng, H.F., Smith, N., Harpaz, R., Bialek, S.R., Sy, L.S., Jacobsen, S.J.: Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 305(2), 160–166 (2011). doi:10.1001/jama.2010.1983 PubMedCrossRef

15.

Schmader, K.E., Levin, M.J., Gnann, J.W., McNeil, S.A., Vesikari, T., Betts, R.F., et al.: Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin. Infect. Dis. (2012). doi:10.1093/cid/cir970

16.

GlaxoSmithKline: Study to Evaluate GSK Biologicals’ Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 50 Years [ClinicalTrials.gov Identifier NCT01165177]. http://clinicaltrials.gov/ct2/show/NCT01165177?term=herpes+zoster&spons=GlaxosmithKline&age=12&phase=2&rank=1 (2011). Accessed 10 December 2011

17.

MoH: Gesetzliche Krankenversicherung Mitglieder, mitversicherte Angehörige und Krankenstand Monatswerte Januar bis February 2012. http://bundesgesundheitsministerium.de/fileadmin/dateien/Downloads/Statistiken/GKV/Mitglieder_Versicherte/KM1_Januar-Februar_2012.pdf (2012). 15 October 2012

18.

Ihle, P., Köster, I., Herholz, H., Rambow-Bertram, P., Schardt, T., Schubert, I.: Versichertenstichprobe AOK Hessen/KV Hessen—Konzeption und Umsetzung einer personenbezogenen Datenbasis aus der Gesetzlichen Krankenversicherung. Das Gesundheitswesen 67, 638–645 (2005). doi:10.1055/s-2005-858598 PubMedCrossRef

19.

Swart, E., Ihle, P., Geyer, S., Grobe, T., Hofmann, W.: GPS—good practice secondary data analysis. Working group for the survey and utilization of secondary data (AGENS) of the German Society for Social Medicine and Prevention (DGSMP). Gesundheitswesen 67(06), 416–421 (2005)PubMedCrossRef

20.

Annemans, L., Bresse, X., Gobbo, C., Papageorgiou, M.: Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J. Med. Econ. 13(3), 537–551 (2010)PubMedCrossRef

21.

WHO: List of ICD-10 classifications. http://apps.who.int/classifications/apps/icd/icd10online/ (2007). Accessed 30 November 2011

22.

Ultsch, B., Siedler, A., Rieck, T., Reinhold, T., Krause, G., Wichmann, O.: Herpes zoster in Germany: quantifying the burden of disease. BMC Infect. Dis. 11(1), 173 (2011)PubMedCrossRef

23.

Gross, G., Schofer, H., Wassilew, S., Friese, K., Timm, A., Guthoff, R.et al.: Herpes zoster guideline of the German Dermatology Society (DDG). J. Clin. Virol. 26(3), 277–289; discussion 291–273 (2003). doi:10.1016/S1386-6532(03)00005-2

24.

Brisson, M.: Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality. Can. J. Public Health 99(5), 383–386 (2008)PubMed

25.

Gauthier, A., Breuer, J., Carrington, D., Martin, M., Remy, V.: Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol. Infect. 137(1), 38–47 (2009). doi:10.1017/S0950268808000678 PubMedCrossRef

26.

Gonzalez Chiappe, S., Sarazin, M., Turbelin, C., Lasserre, A., Pelat, C., Bonmarin, I., et al.: Herpes zoster: burden of disease in France. Vaccine 28(50), 7933–7938 (2010)PubMedCrossRef

27.

Max, M., Schafer, S., Culnane, M., Smoller, B., Dubner, R., Gracely, R.: Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 38(9), 1427 (1988)PubMedCrossRef

28.

Opstelten, W., Mauritz, J.W., de Wit, N.J., van Wijck, A.J., Stalman, W.A., van Essen, G.A.: Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam. Pract. 19(5), 471–475 (2002)PubMedCrossRef

29.

van Hoek, A.J., Gay, N., Melegaro, A., Opstelten, W., Edmunds, W.J.: Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 27(9), 1454–1467 (2009). doi:10.1016/j.vaccine.2008.12.024 PubMedCrossRef

30.

Dworkin, R.H., Portenoy, R.K.: Pain and its persistence in herpes zoster. Pain 67(2–3), 241–251 (1996)PubMedCrossRef

31.

Yawn, B.P.: Post-shingles neuralgia by any definition is painful, but is it PHN? Mayo Clin. Proc. 86(12), 1141–1142 (2011). doi:10.4065/mcp.2011.0724 PubMedCrossRef

32.

Schreyogg, J., Tiemann, O., Busse, R.: Cost accounting to determine prices: how well do prices reflect costs in the German DRG-system? Health Care Manag. Sci. 9(3), 269–279 (2006)PubMedCrossRef

33.

IQWiG: Cost estimation—working paper, Version 1.0. https://www.iqwig.de/download/Working_Paper_Cost_Estimation.pdf (2009). Accessed 22 November 2011

34.

DESTATIS: Lohnnebenkosten im Verhältnis zu den Bruttolöhnen und -gehältern im Jahr 2010. http://www.destatis.de/jetspeed/portal/cms/Sites/destatis/Internet/DE/Presse/pm/2011/04/PD11__143__624,templateId=renderPrint.psml (2011). Accessed 6 February 2012

35.

Krauth, C., Hessel, F., Hansmeier, T., Wasem, J., Seitz, R., Schweikert, B.: Empirical standard costs for health economic evaluation in Germany—a proposal by the working group methods in health economic evaluation. Gesundheitswesen 67(10), 736–746 (2005). doi:10.1055/s-2005-858698 PubMedCrossRef

36.

DESTATIS: Verdienste und Arbeitskosten—Verdienststrukturerhebung 2006, Verdienste nach Berufen (2009). https://www.destatis.de/DE/Publikationen/Thematisch/VerdiensteArbeitskosten/VerdiensteBerufe/VerdienstenachBerufe5621108069004.pdf?__blob=publicationFile. Accessed 6 Mar 2012

37.

DiCiccio, T.J., Efron, B.: Bootstrap confidence intervals. Stat. Sci. 11(3), 189–228 (1996)CrossRef

38.

DESTATIS: Bevölkerung und Erwerbstätigkeit—Bevölkerungsfortschreibung (2010). https://www.destatis.de/DE/Publikationen/Thematisch/Bevoelkerung/Bevoelkerungsstand/Bevoelkerungsfortschreibung2010130107004.pdf?__blob=publicationFile. Accessed 6 Mar 2012

39.

DESTATIS: Consumer price overall index (2011). http://www.destatis.de/jetspeed/portal/cms/Sites/destatis/Internet/EN/Content/Statistics/TimeSeries/EconomicIndicators/BasicData/Content100/vpi102a.psml. Accessed 8 Dec 2011

40.

Welte, R., Feenstra, T., Jager, H., Leidl, R.: A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 22(13), 857–876 (2004). doi:10.2165/00019053-200422130-00004 PubMedCrossRef

41.

OECD: Country statistical profiles. http://www.oecd.org/country/ (2011). Accessed 18 Jan 2012

42.

Paul, E., Thiel, T.: Epidemiology of varicella zoster infection. Results of a prospective study in the Ansbach area. Hautarzt 47(8), 604–609 (1996)PubMedCrossRef

43.

Schiffner-Rohe, J., Jow, S., Lilie, H.M., Köster, I., Schubert, I.: Herpes zoster in Deutschland—Eine retrospektive analyse von GKV-Daten. MMW Fortschr. Med. Orig. IV/2009(151), 193–197 (2009)

44.

Gialloreti, L., Merito, M., Pezzotti, P., Naldi, L., Gatti, A., Beillat, M., et al.: : Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect. Dis. 10(1), 230 (2010)PubMedCrossRef

45.

Donahue, J.G., Choo, P.W., Manson, J.E., Platt, R.: The incidence of herpes zoster. Arch. Intern. Med. 155(15), 1605–1609 (1995)PubMedCrossRef

46.

Cebrian-Cuenca, A., Diez-Domingo, J., San-Martin-Rodriguez, M., Puig-Barbera, J., Navarro-Perez, J.: Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian Community of Spain. BMC Infect. Dis. 11(1), 302 (2011)PubMedCrossRef

47.

Pierik, J., Gumbs, P., Fortanier, S., Van Steenwijk, P., Postma, M.: Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands. BMC Infect. Dis. 12(1), 110 (2012)PubMedCrossRef

48.

Insinga, R.P., Itzler, R.F., Pellissier, J.M., Saddier, P., Nikas, A.A.: The incidence of herpes zoster in a United States administrative database. J. Gen. Intern. Med. 20(8), 748–753 (2005). doi:10.1111/j.1525-1497.2005.0150.x PubMedCrossRef

49.

Leung, J., Harpaz, R., Molinari, N.-A., Jumaan, A., Zhou, F.: Herpes zoster incidence among insured persons in the United States, 1993–2006: evaluation of impact of varicella vaccination. Clin. Infect. Dis. 52(3), 332–340 (2011). doi:10.1093/cid/ciq077 PubMedCrossRef

50.

Tanuseputro, P., Zagorski, B., Chan, K.J., Kwong, J.C.: Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine 29(47), 8580–8584 (2011). doi:10.1016/j.vaccine.2011.09.024 PubMedCrossRef

51.

Yawn, B.P., Saddier, P., Wollan, P.C., St Sauver, J.L., Kurland, M.J., Sy, L.S.: A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin. Proc. 82(11), 1341–1349 (2007)PubMedCrossRef

52.

Schmader, K.E.: Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin. J. Pain 18(6), 350–354 (2002)PubMedCrossRef

53.

Stein, A.N., Britt, H., Harrison, C., Conway, E.L., Cunningham, A., Macintyre, C.R.: Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine 27(4), 520–529 (2009). doi:10.1016/j.vaccine.2008.11.012 PubMedCrossRef

54.

Schiffner-Rohe, J., Köster, I., Beillat, M., Lilie, H.M., Schubert, I.: Ressourcenverbrauch und Kosten von Herpes zoster und postherpetischer Neuralgie in Deutschland. Gesundh. Ökon. Qual. Manag.(EFirst) (2010). doi:10.1055/s-0029-1245896

55.

MacIntyre, C.R., Chu, C.P., Burgess, M.A.: Use of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia. Epidemiol. Infect. 131(1), 675–682 (2003)PubMedCrossRef

56.

Scott, F.T., Johnson, R.W., Leedham-Green, M., Davies, E., Edmunds, W.J., Breuer, J.: The burden of Herpes Zoster: a prospective population based study. Vaccine 24(9), 1308–1314 (2006). doi:10.1016/j.vaccine.2005.09.026 PubMedCrossRef

57.

Insinga, R.P., Itzler, R.F., Pellissier, J.M.: Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans. Pharmacoeconomics 25(2), 155–169. doi: 10.1111/j.1525-1497.2005.0150.x (2007)PubMedCrossRef

58.

Hoffmann, F., Icks, A.: Unterschiede in der Versichertenstruktur von Krankenkassen und deren Auswirkungen für die Versorgungsforschung: Ergebnisse des Bertelsmann-Gesundheitsmonitors. Gesundheitswesen (EFirst) (2011). doi:10.1055/s-0031-1275711

59.

Hoffmann, F., Icks, A.: Diabetes prevalence based on health insurance claims: large differences between companies. Diabet. Med. 28(8), 919–923 (2011). doi:10.1111/j.1464-5491.2011.03305.x PubMedCrossRef

60.

Damm, K., Lange, A., Zeidler, J., Braun, S., Graf von der Schulenburg, J.M.: Einführung des neuen Tätigkeitsschlüssels und seine Anwendung in GKV-Routinedatenauswertungen. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 55(2), 238–244 (2012). doi:10.1007/s00103-011-1418-7 PubMedCrossRef

61.

Zoike, E., Bödeker, W.: Berufliche Tätigkeit und Arbeitsunfähigkeit. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 51(10), 1155–1163 (2008). doi:10.1007/s00103-008-0650-2 PubMedCrossRef

62.

Krauth, C.: Methoden der Kostenbestimmung in der gesundheitsökonomischen Evaluation. Gesundh. Ökon. Qual. Manag. 15(05), 251–259 (2010). doi:10.1055/s-0029-1245680 CrossRef

63.

Greiner, W.: 4. Die Berechnung von Kosten und Nutzen. In: Schöffski, O., Graf von der Schulenburg, J.M. (eds.) Gesundheitsökonomische Evaluation, vol. 3. Springer, Heidelberg (2008)

64.

Luce, B.R., Manning, W.G., Siegel, J.E., Lipscomb, J.: Estimating costs in cost-effectiveness analysis. In: Gold, M.R., Siegel, J.E., Russell, L.B., Weinstein, M.C. (eds.) Cost-Effectiveness in health and medicine. Oxford University Press, New York (1996)

Titel: Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany
verfasst von: Bernhard Ultsch
Ingrid Köster
Thomas Reinhold
Anette Siedler
Gérard Krause
Andrea Icks
Ingrid Schubert
Ole Wichmann
Publikationsdatum: 01.12.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: The European Journal of Health Economics / Ausgabe 6/2013
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-012-0452-1

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2013

How efficient are Greek hospitals? A case study using a double bootstrap DEA approach

Managing for efficiency in health care: the case of Greek public hospitals

Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries

Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information

The cost of Type 1 diabetes mellitus in the United Kingdom: a review of cost-of-illness studies

The impact of generic reference pricing in Italy, a decade on